Emerging Agents for Myelofibrosis

home / insights / myelofibrosis-emerging-agents

Episodes

Overview of Myelofibrosis

December 28th 2018EP. 1: Overview of Myelofibrosis

Diagnosis of Myelofibrosis

December 28th 2018EP. 2: Diagnosis of Myelofibrosis

Prognosis and Risk Stratification of Myelofibrosis

December 28th 2018EP. 3: Prognosis and Risk Stratification of Myelofibrosis

Goals of Therapy and Starting Therapy for Myelofibrosis

December 28th 2018EP. 4: Goals of Therapy and Starting Therapy for Myelofibrosis

NCCN Guidelines and Anemia Treatment

December 28th 2018EP. 5: NCCN Guidelines and Anemia Treatment

Mechanism of JAK Inhibitors and a Review of Ruxolitinib

December 28th 2018EP. 6: Mechanism of JAK Inhibitors and a Review of Ruxolitinib

Long-Term Survival and Adverse Effects With Ruxolitinib

December 28th 2018EP. 7: Long-Term Survival and Adverse Effects With Ruxolitinib

Emerging Agents and Review of Fedratinib

December 28th 2018EP. 8: Emerging Agents and Review of Fedratinib

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

December 28th 2018EP. 9: Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Pacritinib and the Practical Implications

December 28th 2018EP. 10: Pacritinib and the Practical Implications

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

December 28th 2018EP. 11: Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Symptoms and Patient Progression

December 28th 2018EP. 12: Symptoms and Patient Progression

Future of Therapy and Final Thoughts on Myelofibrosis

December 28th 2018EP. 13: Future of Therapy and Final Thoughts on Myelofibrosis

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions